{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:56:38Z","timestamp":1786992998501,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceuticals Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jns.2021.117546","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:33:00Z","timestamp":1624062780000},"page":"117546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life"],"prefix":"10.1016","volume":"428","author":[{"given":"Kazuo","family":"Fujihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Mitsutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Haramura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2021.117546_bb0005","doi-asserted-by":"crossref","first-page":"460825","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","volume":"2012","author":"Oh","year":"2012","journal-title":"Neurol. Res. Int."},{"issue":"4","key":"10.1016\/j.jns.2021.117546_bb0010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis Spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.jns.2021.117546_bb0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2021.117546_bb0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"Pt 6","key":"10.1016\/j.jns.2021.117546_bb0025","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jns.2021.117546_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.jns.2021.117546_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus","volume":"3","author":"Sepulveda","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.jns.2021.117546_bb0040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Multiple Scler. Related Dis."},{"issue":"1","key":"10.1016\/j.jns.2021.117546_bb0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/hex.12432","article-title":"Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study","volume":"20","author":"Methley","year":"2017","journal-title":"Health Expect."},{"key":"10.1016\/j.jns.2021.117546_bb0050","first-page":"8(3)","article-title":"Pain, depression, and quality of life in neuromyelitis optica spectrum disorder","author":"Ayzenberg","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"issue":"3","key":"10.1016\/j.jns.2021.117546_bb0055","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"Asseyer","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.jns.2021.117546_bb0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2016.06.041","article-title":"Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status","volume":"368","author":"Kong","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.jns.2021.117546_bb0065","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fneur.2020.00778","article-title":"Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies","volume":"21","author":"Asseyer","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2021.117546_bb0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.jns.2021.117546_bb0075","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","article-title":"Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study","volume":"77","author":"Kanamori","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2021.117546_bb0080","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/archneurol.2012.768","article-title":"Association of neuromyelitis optica with severe and intractable pain","volume":"69","author":"Qian","year":"2012","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2021.117546_bb0085","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458514522103","article-title":"Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life","volume":"20","author":"Zhao","year":"2014","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jns.2021.117546_bb0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrneurol.2014.129","article-title":"Pain in neuromyelitis optica--prevalence, pathogenesis and therapy","volume":"10","author":"Bradl","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2021.117546_bb0095","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.3390\/jcm9113604","article-title":"Higher disease and pain severity and fatigue and lower balance skills are associated with higher prevalence of falling among individuals with the inflammatory disease of neuromyelitis optica spectrum disorder (NMOSD)","volume":"9","author":"Barzegar","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.jns.2021.117546_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/jnnp-2016-314991","article-title":"Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis","volume":"88","author":"Tackley","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2021.117546_bb0105","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.jns.2021.117546_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"issue":"3","key":"10.1016\/j.jns.2021.117546_bb0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual. Life Res."},{"issue":"4","key":"10.1016\/j.jns.2021.117546_bb0120","first-page":"927","article-title":"Assessment of the impact of vision impairment","volume":"43","author":"Weih","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.jns.2021.117546_bb0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7224\/1537-2073.2017-076","article-title":"Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D","volume":"21","author":"Mealy","year":"2019","journal-title":"Int. J. MS Care."},{"issue":"13","key":"10.1016\/j.jns.2021.117546_bb0130","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/09638288.2013.833301","article-title":"Life on hold: the experience of living with neuromyelitis optica","volume":"36","author":"Mutch","year":"2014","journal-title":"Disabil. Rehabil."},{"issue":"3","key":"10.1016\/j.jns.2021.117546_bb0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/ane.12881","article-title":"Perceptions on the value of bodily functions in multiple sclerosis","volume":"137","author":"Heesen","year":"2018","journal-title":"Acta Neurol. Scand."},{"issue":"12","key":"10.1016\/j.jns.2021.117546_bb0140","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1212\/WNL.0b013e31824c466f","article-title":"Neuromyelitis optica and pregnancy","volume":"78","author":"Bourre","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2021.117546_bb0145","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/1352458515583376","article-title":"Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder","volume":"22","author":"Shimizu","year":"2016","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jns.2021.117546_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11916-017-0620-1","article-title":"Headache in neuromyelitis optica","volume":"21","author":"Masters-Israilov","year":"2017","journal-title":"Curr. Pain Headache Rep."},{"issue":"4","key":"10.1016\/j.jns.2021.117546_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224419","article-title":"Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"15","author":"Masuda","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jns.2021.117546_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3988\/jcn.2020.16.1.124","article-title":"Comparison of neuropathic pain in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"16","author":"Hyun","year":"2020","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jns.2021.117546_bb0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jneuroim.2016.02.011","article-title":"Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression","volume":"293","author":"Shi","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jns.2021.117546_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177230","article-title":"Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life","volume":"12","author":"Seok","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jns.2021.117546_bb0175","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11920-013-0421-0","article-title":"Pain and depression: an integrative review of neurobiological and psychological factors","volume":"15","author":"Goesling","year":"2013","journal-title":"Curr. Psychiatry Rep."},{"issue":"6","key":"10.1016\/j.jns.2021.117546_bb0180","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000286","article-title":"Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder","volume":"3","author":"Chavarro","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2021.117546_bb0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2021.117546_bb0190","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/WCO.0000000000000828","article-title":"Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics","volume":"33","author":"Fujihara","year":"2020","journal-title":"Curr. Opin. Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21002409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21002409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:54:43Z","timestamp":1758383683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21002409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":38,"alternative-id":["S0022510X21002409"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117546","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117546"}}